文献速递肺结节与肺癌

鼻拭子分类器评估肺结节患者肺癌概率

A Nasal Swab Classifier to Evaluate the Probability of Lung Cancer in Patients With Pulmonary Nodules.
PubMed 文献 · Chest · 2023-11-27

该研究验证了一种基于鼻上皮细胞基因组和临床特征的分类器,用于评估吸烟或曾吸烟的肺结节(≤30 mm)患者肺癌概率。在312例独立验证集中,低风险分类敏感度96%、特异度42%,高风险分类敏感度58%、特异度90%,性能优于仅临床风险模型。分类器指导决策可能减少无癌患者诊断操作并让肺癌患者更早治疗。

要点

  • 鼻拭子分类器可对≤30 mm肺结节吸烟者进行低、中、高风险分层。
  • 低风险分类敏感度96%,高风险分类特异度90%。
  • 性能在既往癌症、不同吸烟量及筛查资格亚组中相似。

核心结论

  • 鼻分类器能准确评估吸烟或曾吸烟的≤30 mm肺结节患者的肺癌概率。
  • 分类器指导决策可能减少无癌患者的诊断操作并让肺癌患者更及时治疗。

研究设计与样本

  • 机器学习用1,120例肺结节患者的基因组和临床特征训练分类器,结节良恶性由最终诊断或至少12个月影像监测确定。
  • 分类器在312例独立验证集中验证,包括63例既往有其他癌症史的患者,比较分类器预测与已知临床结局。

主要发现

  • 主要验证集中,低风险分类的敏感度和特异度分别为96%和42%。
  • 高风险分类的敏感度和特异度分别为58%和90%。
  • 敏感度在不同分期非小细胞肺癌中相似,与亚型无关;性能优于仅临床风险模型。
  • 63例既往癌症患者及轻 vs 重吸烟负担、符合 vs 不符合肺癌筛查资格亚组分析性能相似。

关键数值与推荐

  • 低风险分类:敏感度96%,特异度42%。
  • 高风险分类:敏感度58%,特异度90%。
  • 训练集1,120例,验证集312例(含63例既往癌症史)。
  • 纳入标准:肺结节≤30 mm,吸烟或曾吸烟。

临床怎么用

  • 对吸烟或曾吸烟的≤30 mm肺结节患者,可考虑用鼻拭子分类器辅助评估肺癌概率。
  • 低风险分类可支持减少不必要的诊断操作。
  • 高风险分类可支持更及时的治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accurate assessment of the probability of lung cancer (pCA) is critical in patients with pulmonary nodules (PNs) to help guide decision-making. We sought to validate a clinical-genomic classifier developed using whole-transcriptome sequencing of nasal epithelial cells from patients with a PN ≤ 30 mm who smoke or have previously smoked. RESEARCH QUESTION: Can the pCA in individuals with a PN and a history of smoking be predicted by a classifier that uses clinical factors and genomic data from nasal epithelial cells obtained by cytologic brushing? STUDY DESIGN AND METHODS: Machine learning was used to train a classifier using genomic and clinical features on 1,120 patients with PNs labeled as benign or malignant established by a final diagnosis or a minimum of 12 months of radiographic surveillance. The classifier was designed to yield low-, intermediate-, and high-risk categories. The classifier was validated in an independent set of 312 patients, including 63 patients with a prior history of cancer (other than lung cancer), comparing the classifier prediction with the known clinical outcome. RESULTS: In the primary validation set, sensitivity and specificity for low-risk classification were 96% and 42%, whereas sensitivity and specificity for high-risk classification was 58% and 90%, respectively. Sensitivity was similar across stages of non-small cell lung cancer, independent of subtype. Performance compared favorably with clinical-only risk models. Analysis of 63 patients with prior cancer showed similar performance as did subanalyses of patients with light vs heavy smoking burden and those eligible for lung cancer screening vs those who were not. INTERPRETATION: The nasal classifier provides an accurate assessment of pCA in individuals with a PN ≤ 30 mm who smoke or have previously smoked. Classifier-guided decision-making could lead to fewer diagnostic procedures in patients without cancer and more timely treatment in patients with lung cancer.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Lamb CR, Rieger-Christ KM, Reddy C, et al. A Nasal Swab Classifier to Evaluate the Probability of Lung Cancer in Patients With Pulmonary Nodules. Chest. 2023. PMID: 38030063. doi:10.1016/j.chest.2023.11.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。